TrialBone marrow transplantation2011

(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.

K E Abou-Nassar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.